Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
October 17 2017 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced upcoming CR845
presentations at ANESTHESIOLOGY® 2017, the American Society of
Anesthesiologists’ annual meeting, to be held October 21-25, 2017
in Boston.
Presentations will include clinical trial data
for CR845, Cara’s first-in-class peripherally selective kappa
opioid agonist being developed for the treatment of acute and
chronic pain, as well as chronic kidney disease-associated
pruritus.
Details for the presentations are as
follows:
CR845 Oral Abstract Presentation: |
|
|
Title: |
"Respiratory Effects of
I.V. CR845: A Peripherally Acting, Selective Kappa Opioid
Receptor Agonist” |
Abstract
Number: |
JS01 |
Date /
Time: |
Sunday, October 22,
2017; 9:00 a.m. – 12:00 p.m. ET |
Presenter: |
Eugene Viscusi,
M.D., Director, Acute Pain Management, Thomas Jefferson
University |
|
|
Satellite Symposium: |
|
|
Title: |
"A Potential New Path
to Pain Relief: Multimodal Analgesia for Enhanced Recovery
with a Peripherally Acting Kappa Opioid Receptor Agonist
(KORA)” |
Date /
Time: |
Sunday, October 22,
2017; 7:00 – 8:00 a.m. ET |
Presenters: |
Joseph
Stauffer, D.O., M.B.A., Chief Medical Officer, Cara
Therapeutics |
|
Christopher L.
Wu, M.D., Professor, Division of Obstetric Anesthesiology,
Division of Regional Anesthesia and Acute Pain Medicine, Department
of Anesthesiology, The Johns Hopkins Hospital |
For information about ANESTHESIOLOGY® 2017, visit
www.asahq.org/annualmeeting.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors (KORs).
Cara is developing a novel and proprietary class of product
candidates, led by CR845, a first-in-class KOR agonist that targets
the body's peripheral nervous system. In Phase 2 trials, CR845 has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in patients
with moderate-to-severe chronic kidney disease-associated pruritus.
Additionally, CR845 has demonstrated initial signs of efficacy in
patients with moderate-to-severe pain, without inducing many of the
undesirable side effects typically associated with currently
available opioid pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern
Investor Relations, Inc. 212-362-1200 michael@sternir.com
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024